However, pretreatment with Z-VEID-FM significantly attenuated enzalutamide-induced activation of caspase-6 in human drug-sensitive and -resistant glioblastoma cells by 75% and 100%, respectively (Figure 6B). Here, CASP6 is linked to glioblastoma.